Renal Cell Carcinoma

ZIRCON-X: TLX250-CDx PET/CT Changes Management in Indeterminate Renal Masses

Indeterminate renal masses (IRMs) are a common diagnostic challenge, often leading to invasive biopsies, unnecessary surgery, or prolonged surveillance due to imaging uncertainty. The ZIRCON-X...

Latest Posts

Targeting HIF‑2α and VEGF in Post-Immunotherapy RCC: Belzutifan + Lenvatinib Clinical Insights

The combination of belzutifan (WELIREG) plus lenvatinib (LENVIMA) met the primary endpoint of progression-free survival...

FDA Issues CRL for Telix’s Breakthrough Kidney Cancer Imaging Agent TLX250-CDx Over Manufacturing Concerns

The FDA has issued a Complete Response Letter for TLX250-CDx (Zircaix), rejecting the biologics license...

The Effect of GLP-1 Receptor Agonists on Outcomes in Metastatic Renal Cell Carcinoma Patients Undergoing Immune Checkpoint Inhibitor Therapy

GLP-1 agonists in mRCC patients showed 51% lower mortality and reduced immune toxicity with checkpoint...

68Ga-NY104 PET/CT Outperforms 18F-FDG PET/CT in Metastatic ccRCC

68Ga-NY104 PET/CT shows better diagnostic efficacy than 18F-FDG PET/CT in patients with metastatic clear cell...

Genitourinary Oncology Insight Center

About
Contact
Privacy Policy
Terms of Use

About
Contact
Privacy Policy
Terms of Use

732-455-2192
contact@oncologynexus.com

Facebook-f Twitter Google-plus-g Pinterest